Adrenocortical Carcinoma treatment market to stay unaffected by Covid-19
The ongoing pandemic has thrown almost the entire world out of gear. The ones suffering from chronic ailments like cancer need to be extra careful as they are more prone to contracting Covid-19. Still, it wouldn’t be incorrect to state that the Adrenocortical Carcinoma treatment market is unfazed by Covid-19, as very few people contract Adrenocortical Carcinoma. So, even if the vaccine against Covid-19 surfaces mid-2021, the market’s situation would be more or less – the same (except a few alterations in North America due to somewhat more number of people getting Adrenocortical Carcinoma).
The Adrenocortical Carcinoma treatment market is primarily driven by growing incidences of adrenal cortical carcinoma. Also, imaging technologies are advancing. Extensive research is also being carried out on this part. For example – Journal of Clinical Endocrinology & Metabolism identifies Adrenocortical Carcinoma as a highly aggressive and rare malignancy. As of now, the incidence rate comes to 0.7-2 cases in 1 million. Women are more prone to the ailment, that too, those aged between 40 and 50. It needs to be noted that children staying in Brazil are more exposed to Adrenocortical Carcinoma as specific TP53 germline mutation is pretty common in them.
What’s more to Ponder About in Adrenocortical Carcinoma treatment market?
Based on the type of treatment, the Adrenocortical Carcinoma treatment market comprises chemotherapy, surgery, radiation therapy, biologic therapy, and other drug therapy. Surgery could be further categorized as open surgery and laparoscopic surgery. Chemotherapy is sub-categorized as combination therapy comprising etoposide (VP-16) plus mitotane, doxorubicin (Adriamycin), and cisplatin and mitotane (based on kind of drug used to treat Adrenocortical Carcinoma). The “other drug therapy” section implies treating hormonal effects caused due to tumour. Toremifene, tamoxifen, mifepristone, and spironolactone are the drugs enclosed under this type. Radiation therapy says brachytherapy and external beam radiation therapy.
As far as end-users are concerned, the market constitutes speciality cancer clinics, hospitals, diagnostic centres, and others.
The key players in the Adrenocortical Carcinoma treatment market include Bristol-Myers Squibb Company, David Bull Laboratories (Pty) Ltd., Fresenius Kabi, WG Critical care, Mylan Pharmaceuticals, GE Healthcare, Digirad Corporation, NeuroLogica Corp., Hitachi Medical Systems, Pfizer, SINOVISION Technologies (Beijing) Co., Ltd.
What’s with the geographies?
North America leads the Adrenocortical Carcinoma treatment market due to more incidences of Adrenocortical Carcinoma herein. This is evident from the fact that as per the American Cancer Society, 10% of those who undergo adrenal gland’s MRI or CT scan gets diagnosed with adrenal tumours. Europe comes in second. The Asia-Pacific is yet to pick up the pace, due to indolence on the part of patients regarding this rarely occurring ailment.
On the Whole
On the whole, the global Adrenocortical Carcinoma treatment market will continue to grow at its usual pace, irrespective of the onslaught of Covid-19. North America will show some disruption, but otherwise, no major turnaround would be observed.